Hear ye! Hear ye! I have an announcement to make. About 3 months ago, a committee formed to explore the possibility of creating a new conference series for adults with type 1 diabetes. Most conferences are currently geared towards all types of diabetes, but a group of us felt there should be more for the unique challenges that are posed to adults living with type 1.

With that in mind, we are conducting an interest study for the conference. Who would you like to see at the conference? Tell us what is missing from Type 1 diabetes (besides the obvious **cure**). This will help us with programming, as well as securing sponsorships for the event. Besides giving you all you want from the latest and greatest in type 1 diabetes - you have a chance to leave your mark on this revolutionary event. At the end of the survey, there is a question about creating a name for the conference. The committee will choose the winning name. The winner will receive an autographed copy of Know Your Numbers, by Amy Tenderich and Dr. Richard Jackson. The second and third places prizes are a Six Until Me mug and a Diabetes Mine mug, donated by Kerri Morrone and Amy Tenderich.

The survey closes on Friday, September 7, 2007 so don't miss your opportunity to voice your opinion. Take the survey today!!

When TIME magazine does a piece on your plight - it's definitely gaining public interest. The fact that 1 in 3 people affected by Type 1 diabetes manipulate their insulin to lose weight is an eye-opening statistic. This lethal coping mechanism is termed diabulemia and a major national TV show is seeking diabulmics for a "sensitive, accurate portrayal of the condition" - at least that is what they told me.

I volunteered myself for the interview. I've struggled with diabulemia for the past 15 years until I did something a doctor would NEVER recommend. I called the station back - it was CNN. I divulged what a day in the life was like when I practiced diabulemia -- and I was good at it! When I told the interviewer that I noticed a world of difference when I changed my insulin from human synthetic to natural animal, she was surprised (so was my doctor). The key to mitigating my angst with insulin was getting the message to my brain at the same time the rest of my body was getting the glucose. This is less effective in newer insulin analogues. Big Pharma does not profit by selling natural vertebrate insulin even if it is better for hormonal response in suppressing appetite and preventing your body from entering ketoacidosis (DKA). Big Pharma profits if they own the patent for the specific insulin analogue you use. In my land of milk and honey - I realized Big Pharma is not my mom, not my dad and not my best friend. Big Pharma is not personal -- Big Pharma is business. So I took my business elsewhere because I didn't like the way Big Pharma was handling my business.

I don't mind explaining my abusive relationship with insulin if it helps anybody struggling with diabulemia. It's a shameful thing but it doesn't have to be. It's controversial but it's all true. For those of you considering your 15 minutes for diabulemia -- don't be concerned about your privacy. The TV show is planning to shoot the interview in shadow. If you wish to learn more about contributing to this documentary, please see The Sugar Shock.

Circumstances of confusion invalidated a Diamyd clinical trial to protect insulin-producing cells in diabetes patients. This confusion amounts to a speed bump, but Diamyd intends to press on.

The company admitted that the Phase II clinical trial of its gene therapy had been botched following a mix up over which patients received the drug and which got placebo. Diamyd is a vaccine based on GAD65, a major factor for diabetes due to an autoimmune reaction. The company designed the vaccine to reduce the need of insulin injections and prevent the destruction of beta cells that produce insulin in the pancreas. Also, by protecting these cells, it may allow them to regenerate in a non-autoimmune environment, and possibly set the stage for a cure of the disease.

Anders Essen-Möller, CEO of Diamyd, said: "Was the drug mixed up? We do not know. Could there be a mix-up at some other times in the study? Yes it is possible, but that is not certain." Essen-Möller is determined not to let the mistake ruin the vaccine's progress towards approval. Essen-Möller also said he believes that the invalidation of the trial will not adversely affect any ongoing meetings with potential partners.

Once again Diabetes Health gets to the bottom of a breaking point question: why does insulin cost more than ever?

When Fred Banting and Charles Best first discovered insulin in 1921, they sold the patent for a dollar ($1) so that insulin could quickly become available for life-saving use. Within 2 years, Eli Lilly had sold over 60 million units of its purified extract of pig and cow pancreas. Over the next 60 years, purification and duration improvements were applied to insulin. However, each new version of insulin came with a new patent and a higher price tag. By the 80s, yeasts were being used as tiny insulin-making factories. Once the gene for human insulin was inserted into one yeast DNA, the yeast multiplied ad infinitum, and each new yeast came with a little copy of human insulin. This breakthrough, naturally, carried with it a big, profit-making patent.

In 1996, the FDA approved the first insulin analog. Newer insulins are called analogs because they're similar to human insulin-- but not quite exactly. Before being put into the yeast, the human genetic material is slightly changed, to produce slower or quicker acting insulin, for instance. Each one of these improvements comes, of course, with a patent. And all these patented insulins cost - big time. For the entire story, comments from influential diabetes advocates and the evolution of insulin price gouging - see the full article at Diabetes Health!